- Home
- STBA vs RAPT Comparison
STBA vs RAPT Comparison
Compare STBA & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STBA | RAPT |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | STBA | RAPT |
|---|---|---|
| Price | $40.58 | $57.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $43.00 | ★ $56.22 |
| AVG Volume (30 Days) | 241.2K | ★ 4.5M |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ 2.35 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.20 | N/A |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | $11.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.84 | $0.71 |
| 52 Week High | $44.91 | $58.02 |
Technical Indicators
Market Signals| Indicator | STBA | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 37.38 | 78.57 |
| Support Level | $37.06 | $32.00 |
| Resistance Level | $44.14 | N/A |
| Average True Range (ATR) | 1.37 | 0.09 |
| MACD | -0.41 | -0.79 |
| Stochastic Oscillator | 15.91 | 90.91 |
Price Performance
Historical ComparisonAbout STBA S&T Bancorp Inc.
S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. It operates only in one segment which is Community Banking. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.